In a recent bid Onconova Therapeutics Inc. [ONTX] faced a contemporary bid of $0.27 yielding a -8.43% decline where 7.87 million shares have exchanged hands over the last week. ONTX amount got a boost by 2.73% or $0.01 versus $0.26 at the end of the prior session. This change led market cap to move at 54.04M, putting the price 160.18% below the 52-week high and -82.87% above the 52-week low. The company’s stock has a normal trading capacity of 7.87 million shares while the relative volume is 0.47.
On 12, November 2020, Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update. According to news published on Yahoo Finance, ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumors.
Analyst Birdseye View:
The most recent analyst activity for Onconova Therapeutics Inc. [NASDAQ:ONTX] stock was on January 17, 2018, when it was Downgrade with a Hold rating from Maxim Group. Before that, on March 01, 2018, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $7.50. On October 09, 2017, H.C. Wainwright Initiated a Buy rating and boosted its price target on this stock to $6. On April 27, 2017, Laidlaw Initiated a Buy rating and increased its price target to $10. On July 01, 2015, Piper Jaffray Upgrade an Overweight rating. On May 05, 2015, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $6.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.10 and a peak of $1.56. Right now, according to Wall Street analyst the average 12-month amount target is $1.83. At the most recent market close, shares of Onconova Therapeutics Inc. [NASDAQ:ONTX] were valued at $0.27.
Onconova Therapeutics Inc. [NASDAQ:ONTX] most recently reported quarterly sales of 66.0 million, which represented growth of -95.00%. This publicly-traded organization’s revenue is $114,895 per employee, while its income is -$1,131,737 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -103.39, -253.56, -255.87 and -253.56 respectively.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.2598 points at 1st support level, the second support level is making up to 0.2524. But as of 1st resistance point, this stock is sitting at 0.2748 and at 0.2824 for 2nd resistance point.
Onconova Therapeutics Inc. [ONTX] reported its earnings at -$0.03 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.03/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.04 calling estimates for -$0.03/share with the difference of -0.01 depicting the surprise of -33.30%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Onconova Therapeutics Inc. [NASDAQ:ONTX] is 3.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.74. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.52 and it’s amount to book ratio is 3.68.
The most recent insider trade was by Reddy E Premkumar, Director, and it was the sale of 0.53 million shares on Aug 27. Hoffman Michael B, the Director, completed a sale of 0.18 million shares on Aug 27. On Aug 27, Hoffman Michael B, Director, completed a sale of 1876.0 shares.